Seres Therapeutics, Inc. MCRB
Biotechnology: Pharmaceutical Preparations · IPO 2015 · data as of November 13, 2026
Seres Therapeutics, Inc. (MCRB) is a healthcare company listed in the US with a market value of about $14M. In the twelve months to September 30, 2026 it had revenue of $2M and net income of -$47M, a net margin of -2209.6%.
Its overall Stock Analiz score is 0.2 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -71%.
About Seres Therapeutics
Seres Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2015. Revenue went from $22M in 2016 to $7M in 2022, a decline of about 17.0% a year. It was profitable in 2 of the last 10 years in our data. Its share count rose by 64% over three years (dilution for shareholders).
Score: 0.2 / 5
Checks passed
- Strong R&D investment or growth above 20%
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2M | — | — | $0 | $7M | $145M | $33M | $35M | $28M | $32M | $22M |
| Net income | -$47M | $6M | $136000 | -$114M | -$250M | -$66M | -$89M | -$70M | -$99M | -$89M | -$92M |
| Free cash flow | -$64M | $865000 | -$149M | -$125M | -$239M | -$3M | -$94M | -$78M | -$65M | -$80M | $22M |
| EPS (diluted) | $-5.00 | $0.64 | $0.00 | $-17.77 | $-46.20 | $-14.40 | $-22.40 | $-24.80 | $-48.60 | $-44.20 | $-46.00 |
| Net margin | -2209.6% | — | — | — | -3509.5% | -45.2% | -268.3% | -203.7% | -350.0% | -278.4% | -420.7% |
| ROIC | — | -58.4% | -90.9% | -94.9% | -82.0% | -28.2% | -32.3% | — | — | -119.0% | -55.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Seres Therapeutics pay a dividend?
Not currently.
Is Seres Therapeutics a good stock to buy?
We do not give buy or sell advice. Seres Therapeutics scores 0.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.